OneMedNet Reports Third Quarter 2026 Financial Results and Reiterates Fourth Quarter 2026 Outlook
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OneMedNet (ONMD) reported third-quarter 2026 revenue of $1.02 million and reiterated its revenue outlook for the fourth quarter of 2026. Revenue increased 250% from the second quarter of 2026 and 478% from the third quarter of 2025. Revenue for the first nine months of 2026 was $1.41 million. The quarterly result was consistent with the preliminary revenue of approximately $1 million announced on November 6, 2026.
The company reiterated fourth-quarter revenue guidance of approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data by quarter-end. OneMedNet said its sales funnel grew during 2026 and that it began delivering against that funnel at scale in the third quarter. The company expects revenue to occur at a faster pace in the fourth quarter, reflecting order timing and scaled delivery.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter 2026 revenue reached $1.02 million, up 250% sequentially and 478% year over year.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter 2026 revenue guidance reiterated at approximately $12 million to $14 million.
- Moderate pointScaled delivery against the sales funnel began in the third quarter of 2026.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter guidance depends on anticipated customer acceptance of delivered data by quarter-end.
News Explained
The third-quarter figures show that, at
Sources and calculations
- OneMedNet third-quarter 2026 results release (2026-11-17)
- OneMedNet Q3 2026 financial fundamentals (2026-09-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $137,000 / ($1,422,000 / 92) = 8.9 days
Key Figures
- Nine-month revenue
- $1.41 million
- First nine months of 2026
- Third-quarter revenue
- $1.02 million
- Quarter ended September 30, 2026
- Sequential revenue growth
- 250%
- Third quarter 2026 vs. second quarter 2026
- Year-over-year revenue growth
- 478%
- Third quarter 2026 vs. third quarter 2025
- Fourth-quarter revenue guidance
- approximately $12 million to $14 million
- Fourth quarter of 2026; pending anticipated customer acceptance of delivered data
Historical Context
-
Preliminary third-quarter revenue and fourth-quarter guidance were followed by reported results and reiterated guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
real-world data medical
form 10-q regulatory
de-identification technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Nov. 17, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), announced financial results for the third quarter ended September 30, 2026, as reported in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and reiterates its revenue guidance for the fourth quarter of 2026.
The Company reported revenue of
The Company reiterates its revenue guidance of approximately
“Our third quarter results confirm the delivery momentum we previewed earlier this month,” said Aaron Green, President & CEO of OneMedNet. “The hardest work in this business — curating, de-identifying, and delivering regulatory-grade multimodal data at scale — is substantially complete. With our First-Party data coming directly from our healthcare provider partners and a de-identification pipeline and delivery infrastructure built to scale with demand, we are now converting our contracted demand into delivered data, and we remain focused on finishing the year with the fourth quarter we have guided to.”
Third Quarter 2026 Results and Fourth Quarter Outlook Highlights
- Third quarter 2026 revenue of
$1.02 million , consistent with the preliminary revenue of approximately$1 million reported on November 6, 2026. - Sequential growth of
250% over the second quarter of 2026 and year-over-year growth of478% over the third quarter of 2025. - Reiterates fourth quarter 2026 revenue guidance of approximately
$12 million to$14 million , pending anticipated customer acceptance of delivered data by quarter-end.
The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including complete financial statements and management’s discussion and analysis, is available on the SEC’s website at www.sec.gov and in the Investors section of the Company’s website at www.onemednet.com.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our revenue outlook for the fourth quarter of 2026, the timing of revenue recognition, the anticipation of data delivery and customer acceptance, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include but are not limited to our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: Michael.Wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did OneMedNet report for the third quarter of 2026?
OneMedNet reported $1.02 million in third-quarter 2026 revenue, an increase of 250% from the second quarter of 2026 and 478% from the third quarter of 2025.
What is OneMedNet's fourth-quarter 2026 revenue guidance?
OneMedNet reiterated fourth-quarter 2026 revenue guidance of approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data by quarter-end.